anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Revascularization procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are crucial to restore blood flow to the heart and are used in the treatment of myocardial infarction (MI). However, these techniques are known to cause myocardial reperfusion injury in the ischemic heart. The present study aims to mimic ischemia-reperfusion injury in vitro on primary human cardiomyocytes (HCMs) and use the established injury model to study the rescue mechanism of skeletal muscle cell (SkM)-seeded electrospun fiber-coated human amniotic membrane scaffold (EF-HAM) on injured cardiomyocytes through paracrine secretion. An in vitro ischemia-reperfusion injury model was established by exposing the HCM to 5 h of hypoxia, followed by a 6 h reoxygenation period. Six different conditioned media (CM) including three derived from SkM-seeded EF-HAMs were introduced to the injured cells to investigate the cardioprotective effect of the CM. Cell survival analysis, caspase-3 and XIAP expression profiling, mitochondrial membrane potential analysis, and measurement of reactive oxygen species (ROS) were conducted to evaluate the outcomes of the study. The results revealed a significant increase in the viability of HCM exposed to H/R injury by 77.2% (p < 0.01), 111.8% (p < 0.001), 68.7% (p < 0.05), and 69.5% (p < 0.05) when supplemented with HAM CM, EF-HAM 3 min CM, EF-HAM 5 min CM, and EF-HAM 7 min CM, respectively. Furthermore, CM derived from SkM-seeded EF-HAM scaffolds positively impacted hypoxia-/reoxygenation-induced changes in caspase-3 expression, mitochondrial membrane potential, and reactive oxygen species generation, but not in XIAP expression. These findings suggest that EF-HAM composite scaffolds can exert antiapoptotic and cardioregenerative effects on primary human cardiomyocytes through the paracrine mechanism.
Participants will receive matching placebo tablet orally, once daily for 42 days during DB treatment phase in addition to their current antidepressant SSRI/SNRI therapy. Participants who will complete the DB treatment phase (Day 43) may be eligible to participate in a separate 52-week open-label long-term safety study 67953964MDD3003.
The present invention belongs to the technical field of biological medicines, which relates to medicines for preventing and treating retina and cornea neovascularization. The medicines are 4', 5, 7-trihydroxyisoflavone (Genistein, Gen for short) pure products, or bean and relevant vegetable crude extracts containing the Gen, or compound preparations of which the main components are the Gen. The present invention can be prepared into dosage forms, such as, tablets, capsules, oral liquid, vein and muscle injection, liposome, microcapsules, eyedrops, etc. Through whole animal experiments and culture cell experiments, the medicines can obviously inhibit the retina neovascularization of a disease model of a C57BL/6 mouse, and can also inhibit the retina neovascularization of a rabbit and a rat caused by a plurality of factors. The medicines can also inhibit the rabbit's retinal pigment epithelium VEGF and HIF1 protein expression caused by physical anoxia and chemical anoxia. Through the experiments, the medicines can perform the functions of preventing and curing the neovascularization of the retinas and the corneas by inhibiting inducing factor expression of the neovascularization.
A depilatory composition comprising a continuous aqueous phase, a depilatory agent and an oil phase comprising a non-polar oil separated from the continuous phase by a bilayer phase comprising a surfactant and a polar substance. The composition is substantially free from tertiary amines and the polar substance is one or more of polypropylene oxide-15 stearyl ether, olive oil, macadamia nut oil, avocado oil, calendula oil, wheatgerm oil and cyclomethicone. Suitable surfactants include cetearyl phosphate, cetearyl alcohol, cetearyl glucoside, cetostearyl alcohol and ceteareth 20. Suitable non-polar oils include thick mineral oil, sweet almond oil, isohexane, sunflower seed oil, apricot kernel oil and shea butter. The non-polar oil may be present in the form of droplets. The composition may optionally include an accelerator to accelerate keratin reduction, a pH regulator and a clay.
ATG (brand name Thymoglobulin) a polyclonal T cell antibody preparation. It will be given at low doses (0.5 mg/kg Day 1 then 2 mg/kg Day 2).
This study is a prospective, single-arm, open label, single center pilot study to confirm the safety of a ultrahigh frequency DRG stimulator in patients with chronic lower limb pain. The actual trial length is 5 days. An initial eligibility screening within Day -14. Pt admitted to hospital on Day 1. The lead implantation is conducted on Day 2, and the 1st treatment starts after anesthesia recovery (Day 2 T1). If VAS \>4 at 4 hours after the 1st treatment, the 2nd treatment will be conducted. VAS will be acquired 4 hours after the 2nd treatment. On Day 3, physical examination and vital signs will be collected. If VAS \>4, the 3rd treatment will be provided. One hour after the 3rd treatment, the device will be removed and an X-ray will be taken. Three hours after the removal, VAS will be collected and then the patient will be discharged. VAS will be estimated by phone call on Day 4, and the patient will return to OPD for follow up examination on Day 5. The trial is completed on Day 5 visit.
This is open-label (both the participant and the investigator know what treatment participants will receive), prospective (participants are identified and then followed forward in time for the outcome of the study), multi-centre, and non-randomized (participants are assigned to different treatment groups by the investigator) study. The study will be conducted into 2 parts (Part 1 and Part 2). Approximately 400 participants will be enrolled (30 in Part 1 and 370 in Part 2). In Part 1 the optimum dose of cyclophosphamide will be evaluated and in Part 2 the selected dose of cyclophosphamide from Part 1 will be administered. Part 2 will include a screening period of a maximum of 14 days followed by chemotherapy (bortezomib, cyclophosphamide, and dexamethasone) of a maximum of three 21-day cycles. Safety will be evaluated by the assessment of adverse events, vital signs, physical examination, electrocardiogram, and clinical laboratory tests which will be monitored throughout the study.
The subcutaneous implantable cardioverter defibrillator (S-ICD) was developed as an alternative to the traditional transvenous implantable cardioverter defibrillator (TV-ICD), aiming to provide easier implantation, simplified detection algorithm of malignant ventricular arrhythmias and prevention from placing components in the cardiovascular system. The S-ICD is implanted subcutaneously or intramuscularly with the generator placed in the left midaxillary line and the lead tunneled subcutaneously in the left para-sternal region. Preimplant electrocardiogram screening is recommended to prevent implantation in patients at high risk of T wave over-sensing. Currently, the S-ICD is unsuitable for patients requiring pacing or cardiac resynchronization. Since the beginning, the S-ICD underwent extensive preclinical investigation until the first prospective multicentre trial demonstrating high efficacy and safety led to market release. While earlier studies focused on younger patients with higher ejection fraction, more recent studies showed favorable outcomes even in patients with comorbidities similar to those typically observed in patients receiving TV-ICD. The development of second and third generation devices has contributed to reduce inappropriate shocks and overcome previous limitations. The aim of this paper is to review the evidence in the literature over the past decade supporting S-ICD as a valid alternative to TV-ICD in terms of safety and efficacy, highlighting the improvements in technology, as well as outcomes.
Use of zonisamide was frequently associated with central nervous system-related adverse reactions [see Adverse Reactions (6.1)]. The most significant of these can be classified into three general categories: 1) psychiatric symptoms, including depression and psychosis, 2) cognitive dysfunction, and 3) somnolence or fatigue.

Psychiatric Symptoms

In placebo-controlled trials, 2.2% of patients discontinued zonisamide or were hospitalized for depression compared to 0.4% of placebo patients. Among all epilepsy patients treated with zonisamide, 1.4% were discontinued and 1.0% were hospitalized because of reported depression or suicide attempts. In placebo-controlled trials, 2.2% of patients discontinued zonisamide or were hospitalized because of psychosis or psychosis-related symptoms compared to no patients who received placebo. Among all epilepsy patients treated with zonisamide, 0.9% discontinued treatment and 1.4% were hospitalized because of reported psychosis or related symptoms.

Cognitive Dysfunction

Zonisamide, the active ingredient in ZONISADE, causes adverse reactions related to cognitive dysfunction (e.g., psychomotor slowing, difficulty with concentration, and speech or language problems, in particular, word-finding difficulties). In placebo-controlled trials with zonisamide, psychomotor slowing and difficulty with concentration occurred in the first month of treatment and were associated with doses above 300 mg/day. Speech and language problems tended to occur after 6–10 weeks of treatment and at doses above 300 mg/day. Although in most cases these events were of mild to moderate severity, they at times led to withdrawal from treatment.

Somnolence and Fatigue

Somnolence and fatigue were frequently reported CNS adverse events during clinical trials with zonisamide. Although in most cases these events were of mild to moderate severity, they led to withdrawal from treatment in 0.2% of the patients enrolled in controlled trials. Somnolence and fatigue tended to occur within the first month of treatment. Somnolence and fatigue occurred most frequently at doses of 300–500 mg/day.

Risk Amelioration

Prescribers should advise patients against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of ZONISADE is known. Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when ZONISADE is used with other drugs with sedative properties because of potential additive effects.
We estimate that roughly 3000 students will need to be screened to obtain sufficient eligible participants to randomize 150 students. High-risk drinkers will be identified by means of an embedded alcohol screening survey, which will be distributed through Student Health Services. Those deemed eligible through the screening survey and who have agreed to be contacted will be invited to attend a baseline interview, which will further define eligibility and assign interested students to the control or intervention group. Those randomized to the usual care control group will receive a self-help health booklet and will be contacted to complete a follow-up telephone interview at 6, 12, 18 and 24 months. Those randomized to the intervention group will receive the same booklet and will meet with a Student Health Service physician. There will be two face-to-face meetings with the physician and two follow up phone calls by the physician. The physicians use a scripted workbook, diary cards and other materials designed to reduce alcohol use and the frequency of high risk drinking. Those in the intervention group will also be contacted to complete a follow-up telephone interview at 6, 12, 18 and 24 months. Outcome data will also be sought, with participants' permission, from campus organizations including Campus Housing, Security, the RCMP and the Registrar.
The present invention relates to an additive of pigeon food and is made of traditional Chinese drug of pure natural herbs. Plantain herbs, solomonseal, plantain seeds, honeysuckle, astragalus roots, matrimony vine, tropic ageratum, and Chinese angelica roots are prepared according to the weight to form the additive of pigeon food. A method for making the additive of pigeon food comprises the following steps: raw materials are weighed according to the weight and baked; each raw material is ground into the material with less than 100 mesh by a breaking device; the raw materials are uniformly mixed, and the additive of pigeon food is prepared. The additive of pigeon food of the present invention is prepared by traditional Chinese drug which is purely natural. The additive of pigeon food can promote growth and development of a pigeon and can prevent and treat diseases. The meat of the pigeon is become into green food which is purely natural.
A  myostatin multimer comprises two or  more  selected myostatin  immunogens.   Each of  the  myostatin  immunogens independently comprises an amino acid sequence selected from the  group consisting of amino acids 3-18, inclusive of  SEQ ID  NO:4; amino acids 3-15, inclusive of SEQ ID NO:6;  amino acids  3-17,  inclusive, of SEQ ID NO:8; amino  acids  3-16, inclusive  of  SEQ ID NO:10; amino acids 3-22, inclusive  of SEQ  ID  NO:12; amino acids 3-25, inclusive of SEQ ID NO:14; amino acids 3-22, inclusive of SEQ ID NO:16; amino acids  3- 19,  inclusive, of SEQ ID NO:18; amino acids 3-18, inclusive of  SEQ ID NO:20; and amino acids 3-18, inclusive, of SEQ ID NO:22.   Also  described are myostatin multimers  comprising two or more selected myostatin immunogens.  At least one  of the  selected myostatin immunogens comprises the amino  acid sequence  Lys-Arg-Ser-Arg-Arg-Asp (SEQ ID NO:37) or Lys-Glu- Asn-Val-Glu-Lys-Glu  (SEQ ID NO:38) or  Ser-Leu-Lys-Asp-Asp- Asp (SEQ ID NO:39). The  myostatin multimers can be use din vaccine compositions to  elicit an immune response against a myostatin immunogen. The  immune  response  may result in at  least  one  of  the biological effects selected from an increase in body weight, an  increase  in muscle mass, an increase in the  number  of muscle  cells,  an increase in the size of muscle  cells,  a reduction  in  body  fat  content,  am  increase  in  muscle strength,  an increase in mammary gland tissue, an  increase in  lactation, an increase in appetite or feed uptake or  an increase  in  the  life span of the subject.  The  myostatin multimer  can  also be used to manufacture a medicament  for treating a disorder which comprises degeneration or  wasting of muscle.
<P>PROBLEM TO BE SOLVED: To provide a composition of a metal oxide or hydroxide having a fine particle form, excellent in dispersibility in an organic dispersant.  <P>SOLUTION: This fine particle metal oxide or hydroxide-fatty acid complex is produced by passing through the processes of reacting a metal salt with an alkali in the presence of the fatty acid and/or its salt to form the complex of the metal oxide or hydroxide with the fatty acid, then cleaning products other than the complex and drying. As the fine particle metal oxide in the fine particle metal oxide-fatty acid complex, zinc oxide is preferable. As the fatty acid, that of a 6 to 30C is preferable. By passing through such the production processes, the metal oxide/hydroxide complex having a scale like form and easily dispersing in the organic dispersant can be obtained.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Thienopyridines, including Plavix, increase the risk of bleeding. If a patient is to undergo surgery and an antiplatelet effect is not desired, discontinue Plavix five days prior to surgery. In patients who stopped therapy more than five days prior to CABG the rates of major bleeding were similar (event rate 4.4% Plavix + aspirin; 5.3% placebo + aspirin). In patients who remained on therapy within five days of CABG, the major bleeding rate was 9.6% for Plavix + aspirin, and 6.3% for placebo + aspirin. 

Thienopyridines inhibit platelet aggregation for the lifetime of the platelet (7–10 days), so withholding a dose will not be useful in managing a bleeding event or the risk of bleeding associated with an invasive procedure. Because the half-life of clopidogrel's active metabolite is short, it may be possible to restore hemostasis by administering exogenous platelets; however, platelet transfusions within 4 hours of the loading dose or 2 hours of the maintenance dose may be less effective.
PURPOSE:To decrease the burden on a patient and to improve the efficiency of a hospital, by using a computer system having voice recognition and response  function for a diagnostic system of the hospital. CONSTITUTION:The reception is done through the depression of a start switch of an input and output device by a patient, a questionnaire is read out from a memory and specified items are inquired to the patient in voice. When the patient responds to this questionnaire, an audio processing circuit 10 performs audio recognition and the content of recognition is confirmed to the patient. If the content is correct, a diagnostic card is formed and the place to be visited is guided in voice. The patient inputs the card to an input device of the specified diagnostic room and the data of card is stored in a center 6. In the room, a doctor operates the input device and the name of patient registrated in the center 6 is sequentially announced in voice. In addition, the inspection and pharmachy system can also be performed efficiently with a computer system provided with audio recognition and response.
The invention relates to a preparation for treating human papilloma virus, which is prepared by taking rose, Chinese torreya seed, turmeric, pepper, chicory and lophatherum gracile, grinding into powder and preparing into tablets. The rose is soft and comfortable, can astringe and activate blood, and has the effects of treating traumatic injury, breast swelling and pain and the like. Torreya grandis seed has effects of killing parasite, removing food stagnation, moistening dryness, relaxing bowels, and eliminating leucorrhea. Turmeric has the effects of promoting blood circulation and qi circulation, and dredging channels and relieving pain, and can be used for treating blood stasis, qi stagnation, traumatic injury, etc. Zanthoxylum bungeanum has effects of warming middle energizer, eliminating dampness, killing parasites and relieving itching, and is mainly used for treating pruritus vulvae, leukorrhagia and skin pruritus. Chicory has the functions of clearing liver and strengthening stomach, and inducing diuresis to reduce edema, and is mainly used for treating damp-heat jaundice, edema and oliguria. Lophatherum gracile, herba Lophatheri has effects of dispelling pathogenic wind, dredging collaterals, eliminating dampness and relieving spasm, and can be used for treating leprosy, scabies, tinea, scrofula and malignant sore. Thereby achieving the effects of clearing heat, eliminating dampness and clearing HPV.
VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment.

VUSION should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

VUSION should not be used as a substitute for frequent diaper changes. VUSION should not be used to prevent the occurrence of diaper dermatitis, since preventative use may result in the development of drug resistance.
The investigators are initiating a new program dedicated to the research and study of neurodegenerative forms of spinocerebellar ataxia as well and other nucleotide repeat diseases with the exclusion of Huntington's Disease. The analysis will be conducted to provide better clinical, genetic, and pathological characterizations of neurodegenerative forms of spinocerebellar ataxia. The investigators would like to create a repository for samples on these cases as well as prospective cases who are seen via clinic, support groups, referrals etc. The investigators will perform clinical evaluations utilizing ataxia pertinent scales. The investigators project to expand the present genealogical bank by collecting more specimens and identify more families in the process. All this will be performed in collaboration with basic scientists in order to conduct proper laboratory investigation that will help arrive at a cure for neurodegenerative forms of spinocerebellar ataxia and nucleotide repeat diseases excluding Huntington's Disease .
BACKGROUND: Relevant evidence suggests that angiogenic factors contribute significantly to fibril matrix reconstruction following physical injuries to tendon ligaments. Vascular endothelial growth factor A (VEGFA), with its potent angiogenic effect, has been studied extensively, and its functional polymorphisms, including rs699947, rs1570360, and rs2010963, have been the focus of numerous investigations. Some scholars have explored the association between gene polymorphisms in the VEGFA and the risk of tendon ligament injury, but the findings are not entirely consistent.
OBJECTIVES: The purpose of this study was to investigate the association between rs699947, rs1570360, and rs2010963 gene polymorphisms in VEGFA and the risk of tendon and ligament injuries.
METHODS: After including articles about the association of VEGFA rs699947, rs1570360, and rs2010963 polymorphisms with tendon and ligament injuries according to the search strategy, we assessed their quality and conducted meta-analyses to examine the link between these polymorphisms and the risk of tendon and ligament injuries using odds ratios and 95% confidence intervals.
RESULTS: Of 86 related articles, six were included in the meta-analysis. Some of these suggest an association between VEGFA rs2010963 and the risk of tendon and ligament injury in the population, with the specific C allele being one of the adverse factors for knee injury. Some studies suggest that VEGFA rs699947 and VEGFA rs1570360 single-nucleotide polymorphisms are associated with anterior cruciate ligament rupture. The risk of non-contact anterior cruciate ligament rupture is nearly doubled in individuals with the rs699947 CC genotype compared to the control group. Our analysis did not find any significant relationship between VEGFA gene polymorphisms (rs699947, rs1570360, and rs2010963) and the chance of tendon and ligament injury without consideration of race. However, the European population reveals that the CC genotype of VEGFA rs699947 can result in a greater risk of tendon and ligament injury, whereas the AG genotype for rs1570360 provides some protection. Additionally, rs2010963 was significantly associated with tendon and ligament injury; individuals with the C allele and the CC genotype had higher risk. False-positive report probability confirmed the high credibility of our results.
CONCLUSION: Overall, this study found no significant association between VEGFA rs699947, rs1570360, and rs2010963 polymorphisms and the risk of tendon ligament injury. However, in subgroup analysis, some genotypes of VEGFA rs699947, rs1570360, and rs2010963 were found to increase the risk of tendon ligament injury in European populations.